The Cochrane Infectious Diseases Group (CIDG) editorial base is located at the Liverpool School of Tropical Medicine in Liverpool, UK.

Tuberculosis kills 5,000 people every day and over 1,000 people fall sick with TB each day. The great majority of these are the poorest members of our society, with limited access to healthcare and no resources to cope with illness. We know that for any infectious disease the best way to control epidemics is either through vaccines or finding and treating every case to prevent transmission. The only TB vaccine, BCG, is not very effective and this has allowed TB to continue to kill millions of people every year.

_{Members of the IMPPACT Consortium}

_{Back Left: Tracy Seddon, Patrick Walker, Mwayi Madanitsa, Feiko Ter Kuile, Simon Kariuki, Cheryl Giddings | Front Left: Meghna Desai, Annemieke van Eijk, Jayne Webster, Jenny Hill}

The Malaria Genomic Epidemiology Network (MalariaGEN) is an international community of researchers working to understand how genetic variation in humans,Plasmodium parasites, and Anopheles mosquitoes affects the biology and epidemiology of malaria, and using this knowledge to develop more effective ways to control the disease.

MalariaGEN is a scientific network that connects researchers and clinicians in malaria-endemic countries with cutting-edge DNA sequencing technologies and genomic research.

Through a number of multi-centre projects, we provide a framework for generating, integrating and sharing genetic and genomic data, and for investigating key questions about malaria biology and epidemiology. Learn more about how genomics can help to defeat malaria.

The network is coordinated by the MalariaGEN Resource Centre whose members are based primarily at the Wellcome Trust Centre for Human Genetics at the University of Oxford and at the Wellcome Trust Sanger Institute on the Wellcome Genome Campus.

With funding from a Wellcome Trust Collaborative Award, LSTM with partners CNRFP in Burkina Faso, University of Glasgow, University of Durham, Warwick University, Univesity of Oxford and Imperial College have initiated a new three year study on Malaria in Insecticide Resistant Africa (MIRA). This project will quantify the public health impact of insecticide resistance and estimate the finances required to meet malaria control targets in high burden countries where malaria is stubbornly persistent.

RECAP-SL is a €250,000 funded project under the 2nd European & Developing Countries Clinical Trials Partnership (EDCTP2) programme. 

The ReBUILD Consortium was an international health systems research partnership which between 2011 and early 2019 addressed the previously neglected area of health systems research in fragile and conflict-affected settings.

The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership's mission is to serve every person who is vulnerable to TB and ensure that high-quality treatment is available to all who need it.

Together the1300 partners are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programmes, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector.

Stop TB operates through a secretariat hosted by UNOPS in Geneva, Switzerland and seven working groups whose role is to accelerate progress on access to TB diagnosis and treatment; research and development for new TB diagnostics, drugs and vaccines; and tackling drug resistant- and HIV-associated TB. The secretariat is governed by a Coordinating Board that sets strategic direction for the global fight against TB.